Skip to content

Released May 29, 2024, after the close

10-K filed May 29, 2024, 59 days after period end · 0001764013-24-000109

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$75.32MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$59,699,000N/M
Free Cash Flowderived-$59,849,000N/M

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2018
Net Income-$75.32M-$59.43M-$47.17M-$450.00
EPS Diluted———$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR